TY - JOUR
T1 - Musashi 2 (MSI2) expression as an independent prognostic biomarker in non-small cell lung cancer (NSCLC)
AU - Topchu, Iuliia
AU - Karnaukhov, Nikolai
AU - Mazitova, Alexandra
AU - Yugai, Veronika
AU - Voloshin, Mark
AU - Tikhomirova, Mariya
AU - Kit, Oleg
AU - Frantsiyants, Elena
AU - Kharin, Leonid
AU - Airapetova, Tamara
AU - Ratner, Ekaterina
AU - Sabirov, Alexey
AU - Abramova, Zinaida
AU - Serebriiskii, Iliya
AU - Boumber, Yanis
AU - Deneka, Alexander
N1 - Publisher Copyright:
© Journal of Thoracic Disease. All rights reserved.
PY - 2021/3
Y1 - 2021/3
N2 - Background: Musashi-2 (MSI2) is a member of RNA-binding protein family that regulates mRNA translation of numerous intracellular targets and influences maintenance of stem cell identity. This study assessed MSI2 as a potential clinical biomarker in non-small cell lung cancer (NSCLC). Methods: The current study included 40 patients with NSCLC, of whom one presented with stage 1, 14 presented with stage II, 15 presented with stage III, and 10 patients had stage IV. All patients received standard of care treatments. All patient samples were obtained before treatment started. We used immunohistochemical (IHC) approach to measure MSI2 protein expression in matching specimens of normal lung versus tumor tissues, and primary versus metastatic tumors, followed by correlative analysis in relation to clinical outcomes. In parallel, clinical correlative analysis of MSI2 mRNA expression was performed in silico using publicly available datasets (TCGA/ICGC and KM plots). Results: MSI2 protein expression in patient samples was significantly elevated in NSCLC primary tumors versus normal lung tissue (P=0.03). MSI2 elevated expression positively correlated with a decreased progression free survival (PFS) (P=0.026) combined for all stages and with overall survival (OS) at stage IV (P=0.013). Elevated MSI2 expression on RNA level was confirmed in primary tumor versus normal tissue samples in TCGA dataset (P<0.0001), and positively correlated with decreased OS (P=0.02). No correlation was observed between MSI2 expression and age, sex, smoking, and treatment type. Conclusions: Elevated MSI2 expression in primary NSCLC tumors is associated with poor prognosis and can be used as a novel potential prognostic biomarker in NSCLC patients. Future studies in an extended patient cohort are warranted.
AB - Background: Musashi-2 (MSI2) is a member of RNA-binding protein family that regulates mRNA translation of numerous intracellular targets and influences maintenance of stem cell identity. This study assessed MSI2 as a potential clinical biomarker in non-small cell lung cancer (NSCLC). Methods: The current study included 40 patients with NSCLC, of whom one presented with stage 1, 14 presented with stage II, 15 presented with stage III, and 10 patients had stage IV. All patients received standard of care treatments. All patient samples were obtained before treatment started. We used immunohistochemical (IHC) approach to measure MSI2 protein expression in matching specimens of normal lung versus tumor tissues, and primary versus metastatic tumors, followed by correlative analysis in relation to clinical outcomes. In parallel, clinical correlative analysis of MSI2 mRNA expression was performed in silico using publicly available datasets (TCGA/ICGC and KM plots). Results: MSI2 protein expression in patient samples was significantly elevated in NSCLC primary tumors versus normal lung tissue (P=0.03). MSI2 elevated expression positively correlated with a decreased progression free survival (PFS) (P=0.026) combined for all stages and with overall survival (OS) at stage IV (P=0.013). Elevated MSI2 expression on RNA level was confirmed in primary tumor versus normal tissue samples in TCGA dataset (P<0.0001), and positively correlated with decreased OS (P=0.02). No correlation was observed between MSI2 expression and age, sex, smoking, and treatment type. Conclusions: Elevated MSI2 expression in primary NSCLC tumors is associated with poor prognosis and can be used as a novel potential prognostic biomarker in NSCLC patients. Future studies in an extended patient cohort are warranted.
KW - Musashi-2 (MSI2)
KW - Non-small cell lung cancer (NSCLC)
KW - Overall survival (OS)
KW - Prediction biomarkers
KW - RNA binding proteins
UR - http://www.scopus.com/inward/record.url?scp=85103498654&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85103498654&partnerID=8YFLogxK
U2 - 10.21037/jtd-20-2787
DO - 10.21037/jtd-20-2787
M3 - Article
C2 - 33841930
AN - SCOPUS:85103498654
SN - 2072-1439
VL - 13
SP - 1370
EP - 1379
JO - Journal of Thoracic Disease
JF - Journal of Thoracic Disease
IS - 3
ER -